Literature DB >> 25948854

A novel psychoactive substance poses a new challenge in the management of paranoid schizophrenia.

Caroline Anderson1, Christopher Morrell1, David Marchevsky2.   

Abstract

Novel psychoactive substances (NPS), or 'legal highs' are becoming more commonly used as recreational substances in the UK. Their clinical effects are little known and vary considerably between substances. This case discusses a psychiatric inpatient who repeatedly used a stimulant NPS called 'el blanco' while on leave, precipitating relapses of his schizophrenia. The patient initially denied drug use, considering legal highs as different from drugs. The relationship between NPS use and mental state was eventually revealed on careful direct questioning. He recovered and was discharged following treatment with clozapine and education about NPS use. We suggest that specific questioning about NPS usage is added to routine psychiatric history taking and that patients using NPS should be educated about the substances' use. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25948854      PMCID: PMC4434264          DOI: 10.1136/bcr-2015-209573

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  18 in total

1.  "Legal highs" on the net-Evaluation of UK-based Websites, products and product information.

Authors:  Martin M Schmidt; Akhilesh Sharma; Fabrizio Schifano; Charlotte Feinmann
Journal:  Forensic Sci Int       Date:  2010-07-21       Impact factor: 2.395

2.  Novel psychoactive substances: a novel clinical challenge.

Authors:  Christopher Daniel Smith; Margaret Williams; Maliha Shaikh
Journal:  BMJ Case Rep       Date:  2013-08-20

3.  An analysis of legal highs: do they contain what it says on the tin?

Authors:  Mark Baron; Mathieu Elie; Leonie Elie
Journal:  Drug Test Anal       Date:  2011-05-19       Impact factor: 3.345

4.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

5.  Mephedrone use and associated adverse effects in school and college/university students before the UK legislation change.

Authors:  P I Dargan; S Albert; D M Wood
Journal:  QJM       Date:  2010-07-30

Review 6.  Using poisons information service data to assess the acute harms associated with novel psychoactive substances.

Authors:  D M Wood; S L Hill; S H L Thomas; P I Dargan
Journal:  Drug Test Anal       Date:  2014-05-15       Impact factor: 3.345

Review 7.  'Legal highs'--novel and emerging psychoactive drugs: a chemical overview for the toxicologist.

Authors:  Simon Gibbons
Journal:  Clin Toxicol (Phila)       Date:  2012-01       Impact factor: 4.467

8.  "Legal highs": safe and legal "heavens"? A study on the diffusion, knowledge and risk awareness of novel psychoactive drugs among students in the UK.

Authors:  Ornella Corazza; Pierluigi Simonato; John Corkery; Giuseppina Trincas; Fabrizio Schifano
Journal:  Riv Psichiatr       Date:  2014 Mar-Apr       Impact factor: 1.911

Review 9.  Effects and risks associated with novel psychoactive substances: mislabeling and sale as bath salts, spice, and research chemicals.

Authors:  Nicolas Hohmann; Gerd Mikus; David Czock
Journal:  Dtsch Arztebl Int       Date:  2014-02-28       Impact factor: 5.594

10.  Harm reduction and knowledge exchange-a qualitative analysis of drug-related Internet discussion forums.

Authors:  Christophe Soussan; Anette Kjellgren
Journal:  Harm Reduct J       Date:  2014-09-08
View more
  1 in total

1.  Pharmacotherapy of Patients Taking New Psychoactive Substances: A Systematic Review and Analysis of Case Reports.

Authors:  Michal Ordak; Aleksandra Zmysłowska; Miłosz Bielski; Daniel Rybak; Maja Tomaszewska; Katarzyna Wyszomierska; Aleksandra Kmiec; Natalia Garlicka; Maria Zalewska; Michal Zalewski; Tadeusz Nasierowski; Elzbieta Muszynska; Magdalena Bujalska-Zadrozny
Journal:  Front Psychiatry       Date:  2021-04-23       Impact factor: 4.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.